Meta-analysisindependent cross-checkabstract checked I-SRC-111 standard review
How much statins help in absolute terms
Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.
Overview
Byrne P et al.. JAMA Intern Med 2022 · PMID 35285850 · DOI 10.1001/jamainternmed.2022.0134
Statins lowered death by 0.8, heart attacks by 1.3 and strokes by 0.4 percentage points over the trials.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Quantify absolute statin benefit
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
21 trials
- What was actually found?
Modest absolute but real reductions
- How large was the observed effect?
ARR 0.8% death; 1.3% MI; 0.4% stroke
- What do the results mean in everyday life?
Benefit depends on personal risk
- What are the study's limitations?
Heterogeneity
- What does it say about Elawady's specific claim?
Supports individual choice, not a ban
- Do the results apply to Germany and Europe?
High
Scientific in-depth review
1. Full reference
- Authors
- Byrne P et al.
- Journal
- JAMA Intern Med
- Year
- 2022
- Identifier
- PMID 35285850 DOI 10.1001/jamainternmed.2022.0134
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works record checked
- Retracted
- no
- Corrections
Erratum published: JAMA Intern Med. 2022 May 1;182(5):579. doi: 10.1001/jamainternmed.2022.1671.
- Extent checked
- abstract only
- Conflicts of interest and funding
None reported; erratum published (JAMA Intern Med 2022;182(5):579).
2. Research question
How large are absolute versus relative effects of statins on mortality, MI and stroke?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and meta-analysis of RCTs with meta-regression
- Population
Adults in 21 large statin trials
- Country
International
- Period
Searches 1987-June 2021
- Sample size
21 trials
- Inclusion and exclusion criteria
Large RCTs >=2 years reporting LDL change
4. Methods and endpoints
- Exposure / intervention
Statin
- Comparator
Placebo/usual care
- Endpoints
All-cause mortality, MI, stroke
- Statistical methods
Meta-analysis, meta-regression, GRADE
5. Actual results
- Results
Absolute risk reductions: all-cause mortality 0.8% (0.4%-1.2%), MI 1.3% (0.9%-1.7%), stroke 0.4% (0.2%-0.6%); relative risk reductions 9% (5%-14%), 29% (22%-34%), 14% (5%-22%). Meta-regression on LDL reduction inconclusive.
- Absolute risks
ARR 0.8% mortality, 1.3% MI, 0.4% stroke over trial durations.
- Authors' conclusion
Absolute risk reductions are modest compared with relative reductions; absolute effects should be discussed in shared decision-making.
6. Strengths
- RoB 2 and GRADE
- Focus on absolute effects
7. Weaknesses
- Mixed primary/secondary prevention
- Significant heterogeneity
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Heterogeneity reduces certainty.
9. Assessment of the statistical interpretation
ARR 0.8% -> NNT about 125 for mortality, 77 for MI, 250 for stroke over trial follow-up (stats/C-SRC-60_statins.py). Benefits are real but depend on baseline risk.
10. Relevance to the specific claim
Supporting side (partly): for many people the absolute benefit of statins is modest, which justifies individual decisions; it still shows reductions in death, MI and stroke and therefore contradicts a ban.
11. Independent contrary findings
I-INTB-18 (CTT: 22% fewer vascular events per mmol/L).
12. Transferability to Germany and Europe
Applicable.
13. Overall methodological judgement
Balanced evidence: benefit real but modest in absolute terms.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- For six or seven years he alone has said that statins (Crestor, Ator, Lipitor) are forbidden, and that Controloc (pantoprazole) is forbidden. – Studies with mixed or unclear results